TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Rachel A. Freedman, Rebecca Sue Gelman, Jeffrey Scott Wefel, Ian E. Krop, Michelle E. Melisko, Alarice Lowe, Nathalie Agar, Kimberly L. Blackwell, Roisin M. Connolly, Polly Ann Niravath, Catherine H. Van Poznak, Shannon Puhalla, Nicole Ryabin, Elizabeth S Lawler, Nuhad K. Ibrahim, Minetta C. Liu, Antonio C. Wolff, Eric P. Winer, Nancy U. Lin
Institutions: Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center, Brigham and Women's Hospital, Duke University, Duke Cancer Institute, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baylor College of Medicine, U-M Rogel Cancer Center, Magee-Womens Hospital, University of Pittsburgh Medical Center, Mayo Clinic, Johns Hopkins Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2598258962